The role of diagnostic laparoscopy in the treatment of patients with ovarian tumors

2021 ◽  
Vol 50 (3) ◽  
pp. 57-60
Author(s):  
E. I. Gulo ◽  
S. Ya. Maksimov ◽  
A. M. Shcherbakov
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Tumor ◽  
Diagnostic Laparoscopy ◽  
Tumor Development ◽  
Early Recurrence ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Diagnostic Difficulties ◽  
Ovarian Neoplasia

The aim of the investigation was to study the role of diagnostic laparoscopy in treatment of patients with ovarian cancer. The analysis of 480 laparoscopic operations, which was carried out on 42 patients with benign tumors, 29 cases of suspected tumor malignization, 67 patients with non gynecological pathology with suspected ovarian neoplasia and 174 women with established ovarian cancer, made it possible to define indications to laparoscopic operations. Using this method the authors managed to solve differential-diagnostic difficulties in 81,7% cases. The results of the investigation revealed the advantages of the method as to patients with benign tumors. This method is recommended for ovarian tumor and early recurrence diagnostics and also for morphological verification of tumor development. But the role of laparoscopy in treatment of malignant ovarian cancer, especially its early forms, still has to be further investigated.

ROLE OF LIPID PROFILE IN OVARIAN CARCINOMA PATIENTS

2019 ◽  
Vol 3 (8) ◽  
Author(s):  
Dr. Manisha ◽  
Dr. Ruchi Jindal
Keyword(s):  
Ovarian Cancer ◽  
Lipid Profile ◽  
Cancer Patients ◽  
Ovarian Tumor ◽  
Ovarian Cancer Risk ◽  
Low Level ◽  
Medical College ◽  
Group I ◽  
History Of

Background: The term "ovarian cancer" includes several different types of cancer that  arise from cells of the ovary, most commonly, tumors arise from the epithelium or lining cells of the ovary.  Ovarian cancer risk is positively associated with higher consumption of dietary cholesterol and eggs, and inversely associated with a higher intake of vegetables. High consumption of fats may increase circulating estrogen levels, thus increasing the possibility of cell damage and proliferation that is responsible for cancerous growth. Material & Methods: The present study was conducted at Geetanjali Medical College and Hospital, Udaipur (Rajasthan). Total  100 cases (females) attending the obstetrics and gynecology department for some gynecological and other problem  were selected for this study between the age of 40-60 years, who were attending cancer centre at GEETANJALI MEDICAL COLLEGE AND  HOSPITAL, Udaipur (Rajasthan).                GROUP I: - It consisted of healthy females control subjects (n=50) .By routine examination and tests, we ensured that all the subjects were healthy and there were no signs and symptoms or history of ovarian tumor and diseases GROUP II: - It consisted of ovarian cancer females subjects (n=50) with a history of ovarian tumor. Results:   Higher level of cholesterol, LDL, VLDL and low level of HDL are found in ovarian cancer patients. Conclusion: The present study we highlights the importance and role of serum lipid profile in diagnosis, prognosis and recurrence of the disease. The study shows that serum level of cholesterol, LDL, VLDL was elevated in  patients of ovarian cancer while low level of HDL are found in ovarian cancer patients. Key words: lipid profile, ovarian cancer.

scholarly journals Role of CA 19-9 in complex ovarian tumors

2016 ◽  
Author(s):  
Dhanya S. Thomas ◽  
Ajit Sebastian ◽  
Vinotha Thomas ◽  
Anitha Thomas ◽  
Rachel Chandy ◽  
...  
Keyword(s):  
Malignant Tumors ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Ovarian Mass ◽  
Radiological Findings ◽  
Epithelial Tumors ◽  
Mucin Glycoprotein ◽  
Glycoprotein Antigen ◽  
Mucinous Tumours

Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, wereincluded in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 - benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors.Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were non mucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.

scholarly journals Serum Vascular Endothelial Growth Factor VEGF and Interlukin-8 As a Novel Biomarkers For Early Detection of Ovarian Tumors

2015 ◽  
Vol 12 (2) ◽  
pp. 293-300
Author(s):  
Baghdad Science Journal
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Serum Levels ◽  
Elisa Test ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Vascular Endothelial ◽  
Additional Tool ◽  
Novel Biomarkers ◽  
Endothelial Growth Factor

Epithelial ovarian cancer is the leading cause of cancer deaths from gynecological malignancies. Angiogenesis is considered essential for tumor growth and the development of metastases. VEGF and IL?8 are potent angiostimulatory molecules and their expression has been demonstrated in many solid tumors, including ovarian cancer.VEGF and IL-8 concentrations were measured by ELISA test (HumanVEGF,IL-8). Bioassay ELISA/ US Biological / USA).The median VEGF and IL-8 levels were significantly higher in the sera of ovarian cancer patients than in those with benign tumors and in healthy controls.Pretreatment VEGF and IL-8 serum levels might be regarded as an additional tool in the differentiation of ovarian tumors.

Immune cells of the epithelial ovarian cancer microenvironment

2021 ◽  
pp. 67-78
Author(s):  
Varvara Nikolaevna Zhurman ◽  
Natalia Gennadevna Plekhova ◽  
Ekaterina Valeryevna Eliseeva
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Immune Cells ◽  
Ovarian Tumor ◽  
Biologically Active ◽  
Cancer Microenvironment ◽  
Review Of The Literature ◽  
Prognostic Role ◽  
Active Substances

The article is a review of the literature, which analyzes the data on the role of cells of the immune system, cytokines and other biologically active substances secreted by them in the interstitial space of an ovarian tumor. The emphasis is made on the mechanism of realization by immune cells of the stimulating and suppressing action on the development of the tumor. Considerable attention is paid to the prognostic role of immune cells in the development of epithelial ovarian cancer.

scholarly journals Metagenomic Analysis of Serum Microbe-Derived Extracellular Vesicles and Diagnostic Models to Differentiate Ovarian Cancer and Benign Ovarian Tumor

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1309 ◽  
Author(s):  
Se Ik Kim ◽  
Nayeon Kang ◽  
Sangseob Leem ◽  
Jinho Yang ◽  
HyunA Jo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Vesicles ◽  
Ovarian Tumor ◽  
Ovarian Tumors ◽  
Metagenomic Analysis ◽  
Serum Samples ◽  
Benign Ovarian Tumor ◽  
Diagnostic Models ◽  
Test Sets ◽  
Benign Ovarian Tumors

We aimed to develop a diagnostic model identifying ovarian cancer (OC) from benign ovarian tumors using metagenomic data from serum microbe-derived extracellular vesicles (EVs). We obtained serum samples from 166 patients with pathologically confirmed OC and 76 patients with benign ovarian tumors. For model construction and validation, samples were randomly divided into training and test sets in the ratio 2:1. Isolation of microbial EVs from serum samples of the patients and 16S rDNA amplicon sequencing were carried out. Metagenomic and clinicopathologic data-based OC diagnostic models were constructed in the training set and then validated in the test set. There were significant differences in the metagenomic profiles between the OC and benign ovarian tumor groups; specifically, genus Acinetobacter was significantly more abundant in the OC group. More importantly, Acinetobacter was the only common genus identified by seven different statistical analysis methods. Among the various metagenomic and clinicopathologic data-based OC diagnostic models, the model consisting of age, serum CA-125 levels, and relative abundance of Acinetobacter showed the best diagnostic performance with the area under the receiver operating characteristic curve of 0.898 and 0.846 in the training and test sets, respectively. Thus, our findings establish a metagenomic analysis of serum microbe-derived EVs as a potential tool for the diagnosis of OC.

scholarly journals Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy

2020 ◽  
Vol 2020 ◽  
pp. 1-15 ◽  
Author(s):  
Monika Bilska ◽  
Anna Pawłowska ◽  
Ewelina Zakrzewska ◽  
Agata Chudzik ◽  
Dorota Suszczyk ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Th17 Cells ◽  
Prognostic Significance ◽  
Clinicopathological Characteristics ◽  
Lower Percentage ◽  
Benign Tumors ◽  
Control Group ◽  
Intracellular Expression ◽  
Benign Ovarian Tumors

Ovarian cancer (OC) is usually diagnosed at an advanced stage and is related with poor prognosis. Despite numerous studies, the pathogenesis of OC is still unknown. Recent studies indicate the role of the immune system in the development and spread of OC. The identification of factors and mechanisms involved in that process and their modulation is crucial for creating effective antitumor therapy. We investigated the potential role of Th17 cells in OC patients (n = 71) by analyzing the frequencies of Th17 cells in three different environments, i.e., peripheral blood (PB), peritoneal fluid (PF), and tissue (Th17 infiltrating cells), and the concentration of IL-17A in plasma and PF of patients in terms of their clinical and prognostic significance. Th17 cells were analyzed by flow cytometry as a percentage of CD4+ lymphocytes that expressed intracellular expression of IL-17A. The level of IL-17A in plasma and PF were determined by ELISA. Our results showed accumulation of Th17 cells among tumor-infiltrating CD4+ lymphocytes (p<0.001 in relation to PB). Moreover, the percentage of Th17 cells in both PB and PF of OC patients was significantly lower than that in benign tumors group (n = 35). There were no significant differences in the percentage of Th17 cells in PB, PF, and tissue in relation to clinicopathological characteristics of OC patients and survival. The lower percentage of Th17 cells in the PB and PF of OC patients may promote evasion of host immune response by cancer cells. The concentration of IL-17A in plasma of OC patients was higher (p<0.0001) than that in both benign tumors and control group (n = 10). The PF IL-17A level in OC patients was higher (p<0.0001) than that in women with benign ovarian tumors, indicating its synthesis in OC microenvironment. Higher IL-17A level in PF is correlated with longer (median: 36.5 vs. 27 months) survival of OC patients.

Surface epithelial tumors of ovary - an analysis in a tertiary referral hospital

2013 ◽  
Vol 3 (5) ◽  
pp. 397-402 ◽  
Author(s):  
D Ghartimagar ◽  
A Ghosh ◽  
G KC ◽  
S Ranabhat ◽  
OP Talwar
Keyword(s):  
Ovarian Cancer ◽  
Malignant Tumors ◽  
Data Bank ◽  
Serous Cystadenoma ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Tertiary Referral ◽  
Tertiary Referral Hospital ◽  
Tertiary Referral Centre ◽  
Epithelial Tumors

Background: Ovarian cancer accounts for 3% of all cancers in females. About 80% of these are benign, and they occur mostly in young women between 20 and 45 years. Borderline tumors occur at slightly older ages while incidence of malignant tumors increases with age, occurring predominantly in perimenopausal and postmenopausal women. About 190,000 new cases and 114,000 deaths from ovarian cancer are estimated to occur annually worldwide. The aim of the study was to fi nd the incidence of surface ovarian tumor in a tertiary referral centre. Materials and methods: This was a retrospective study carried out in the department of pathology, Manipal Teaching Hospital from January 2001 to December 2012. Specimens were received from the same and other hospitals. Records were retrieved from the departmental data bank and were analyzed. Results: : A total of 310 cases of ovarian tumors have been reported in the same period. Among them, 180 cases were of surface epithelial origin and out of which 24 cases had bilateral tumors. Benign tumors comprised of 148 cases, 6 were borderline and 44 were malignant. Among these, the commonest was serous cystadenoma (98 cases) and the least common was malignant Brenner (2 cases). Combined or mixed tumor was seen in 9 cases. Conclusion: : In our study surface epithelial tumors comprised 58% of all ovarian tumors. In both benign and malignant cases, serous tumor was the commonest followed by mucinous tumors. Journal of Pathology of Nepal (2013) Vol. 3, No.1, Issue 5, 397-402 DOI: http://dx.doi.org/10.3126/jpn.v3i5.7868

scholarly journals Preoperative Measurement of Serum C-Reactive Protein: Is it Useful in the Differential Diagnosis of Adnexal Masses?

2017 ◽  
Vol 32 (1) ◽  
pp. 83-89 ◽  
Author(s):  
Adriana Yoshida ◽  
Sophie F. Derchain ◽  
Denise R. Pitta ◽  
Nathália Crozatti ◽  
Liliana A.L.A. Andrade ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Sensitivity And Specificity ◽  
Menopausal Status ◽  
Ovarian Tumors ◽  
Cancer Center ◽  
Benign Tumors ◽  
C Reactive Protein ◽  
Cross Sectional ◽  
Adnexal Masses ◽  
Reactive Protein

Background Serum biomarkers may help to discriminate malignant from benign adnexal masses with equivocal features on imaging. Adequate discrimination of such tumors is crucial for referring patients to either a specialized cancer center or a nonspecialized gynecology service. Aim We aimed to investigate whether the preoperative level of serum C-reactive protein (CRP), alone or combined with CA125 and menopausal status in the Ovarian Score (OVS), is useful in the prediction of malignancy in women with ovarian tumors. Methods This cross-sectional study included 293 patients who underwent surgery in a tertiary cancer center. Receiver operating characteristic (ROC) areas under the curves (AUC) for CRP, CA125 and OVS were calculated in different scenarios, as well as their sensitivity and specificity, using standard cutoff points (for CRP, 10 mg/L; for CA125, 35 U/mL). Results CA125 and the OVS performed significantly better than CRP alone in the differentiation of benign disease from epithelial ovarian cancer (EOC) (AUC = 0.86 for CA125, 0.79 for OVS, and 0.73 for CRP). OVS and CRP alone were superior to CA125 only in the differentiation of borderline ovarian tumors from advanced stages of EOC and non-EOC. Sensitivity and specificity were 52.5% and 83%, respectively, for CRP, 77.9% and 66.7% for CA125, and 71.3% and 67.8% for OVS. Conclusions OVS is as good as CA125 in the differentiation of benign tumors from ovarian cancer. The addition of CA125 and menopausal status to CRP enhanced the relatively low discriminatory power of isolated CRP.

scholarly journals Urinary Polyamines as Biomarkers for Ovarian Cancer

2017 ◽  
Vol 27 (7) ◽  
pp. 1360-1366 ◽  
Author(s):  
Riikka Johanna Niemi ◽  
Antti N. Roine ◽  
Merja R. Häkkinen ◽  
Pekka S. Kumpulainen ◽  
Tuomo A. Keinänen ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Ovarian Cancer ◽  
Malignant Potential ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Tandem Mass ◽  
High Grade ◽  
Chromatography Tandem Mass Spectrometry ◽  
Low Malignant Potential ◽  
Liquid Chromatography Tandem Mass

ObjectivesElevated concentrations of polyamines have been found in urine of patients with malignant tumors, including ovarian cancer. Previous research has suffered from poorly standardized detection methods. Our liquid chromatography–tandem mass spectrometry (LC-MS/MS) method is capable of simultaneous standardized analysis of most known polyamines. Liquid chromatography–tandem mass spectrometry has not previously been used in the differential diagnostics of ovarian tumors in postmenopausal women.Materials and MethodsIn this prospective study, postmenopausal women (n = 71) presenting with an adnexal mass and, as controls, women with genital prolapse or urinary incontinence scheduled for surgery (n = 22) were recruited in the study. For analysis of the polyamines, a morning urine sample was obtained before surgery. Preoperative serum CA125 concentrations were determined in the study group.ResultsTwenty-three women with benign and 37 with malignant ovarian tumors were eligible. Of all analyzed polyamines, only urinaryN1,N12-diacetylspermine showed statistically significant differences between all groups except controls versus benign tumors.N1,N12-diacetylspermine was elevated in malignant versus benign tumors (P< 0.001), in high-grade versus low malignant potential tumors (P< 0.001), in stage III to IV versus stage I to II cancers (P< 0.001), and even in early-stage cancer (stage I–II) versus benign tumors (P= 0.017).N1,N12-diacetylspermine had better sensitivity (86.5%) but lower specificity (65.2%) for distinguishing benign and malignant ovarian tumors than CA125 with a cut-off value of 35 kU/L (sensitivity, 75.7%; specificity, 69.6%).ConclusionsUrinaryN1,N12-diacetylspermine seems to be able to distinguish benign and malignant ovarian tumors as well as early and advanced stage, and low malignant potential and high-grade ovarian cancers from each other, respectively.

Sign in / Sign up

Export Citation Format

Share Document